All In Biotech

Drug Trial Radar · NCT07941609

A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC

A Global, Multicentre, Phase II Platform Study of Datopotamab Deruxtecan (Dato-DXd)-Based Combinations in Adult Participants With TROP2 NMR-positive Non-small Cell Lung Cancer (NSCLC) (PATAGONIA)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Dec 16, 2028

Study completion Dec 22, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • Dato-DXdDrug

    Treatment A/B: Dato-DXd as IV infusion.

  • DurvalumabDrug

    Treatment A/B: Durvalumab as IV infusion

  • CarboplatinDrug

    Treatment B: Carboplatin as IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS as assessed by investigator on Treatment ATime frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months
  2. PFS as assessed by investigator on Treatment BTime frame: Date of first dose of study intervention until disease progression per RECIST 1.1 or death from any cause, or end of study whichever occurs first, up to approximately 30 months

Locations

87 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Irvine, California

  • Research Site

    Oakland, California

  • Research Site

    Golden, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Miami, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Peoria, Illinois

  • Research Site

    Greer, South Carolina

  • Research Site

    Greer, South Carolina

  • Research Site

    Sugar Land, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Morgantown, West Virginia

  • Research Site

    Ciudad Autonoma Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    La Rioja, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    San Juan, Argentina

  • Research Site

    Viedma, Argentina

  • Research Site

    Adelaide, Australia

  • Research Site

    Bedford Park, Australia

  • Research Site

    Southport, Australia

  • Research Site

    Waratah, Australia

  • Research Site

    Woodville, Australia

  • Research Site

    Blumenau, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Ijuí, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Salvador, Brazil

  • Research Site

    Santa Maria, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Teresina, Brazil

  • Research Site

    Vitória, Brazil

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Brampton, Ontario, Canada

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.